MEF2D and ovarian cancer: The results showed that the MEF2D gene in ovarian cancer cells treated with R-Se@MEF2D-siRNA was inhibited, blocking the WNT/β-catenin pathway, thereby reducing VEGF secretion in the non-immune TME, reducing vascularization, thereby reducing nutrient and oxygen supply to tumors, and inhibiting AOC cell proliferation (Figure 4B).